4th Quarter - Report

THE CARLYLE GROUP for THE CARLYLE GROUP

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$370,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 20, 2021 $370,000 Replaced
4th Quarter - Amendment Jan 7, 2022 $400,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to healthcare provisions included in the Coronavirus Aid, Relief, and Economic Security Act (H.R. 748), including those affecting telehealth; Issues related to diagnostic testing; Issues related to vaccine manufacturing and distribution.

LobbyistCovered position, as disclosed
STACEY DION —
CHASE HIENEMAN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Securities & Exchange Commission (SEC); SENATE

Bills named: H.R. 748 (116th)

Housing HOU

Housing policy related to COVID-19 response.

LobbyistCovered position, as disclosed
MINH TA —

Contacted: Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); SENATE; HOUSE OF REPRESENTATIVES; Treasury, Dept of

Aviation/Airlines/Airports AVI

Airline and airport relief provisions in the Coronavirus Aid, Relief, and Economic Security Act (H.R. 748).

LobbyistCovered position, as disclosed
STACEY DION —
MINH TA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Securities & Exchange Commission (SEC); Food & Drug Administration (FDA); Treasury, Dept of

Bills named: H.R. 748 (116th)

Financial Institutions/Investments/Securities FIN

Issues related to lending facilities, economic grants, and other Federal Reserve responses to COVID-19; Issues related to business development companies, private credit, and SEC fund expense reporting rule.

LobbyistCovered position, as disclosed
STACEY DION —
MINH TA —

Contacted: Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Treasury, Dept of

Taxation/Internal Revenue Code TAX

Issues related to tax provisions included in the Coronavirus Aid, Relief, and Economic Security Act (H.R. 748); Issues related to the Tax Cuts and Jobs Act.

LobbyistCovered position, as disclosed
STACEY DION —

Contacted: Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE

Bills named: H.R. 748 (116th)

Budget/Appropriations BUD

Issues related to loans and grants authorized and appropriated under the Coronavirus Aid, Relief, and Economic Security Act (H.R. 748); Issues related to eligible businesses under Division A Title IV subtitle A of H.R. 748.

LobbyistCovered position, as disclosed
STACEY DION —

Contacted: Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of

Bills named: H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.